Inspire Medical Systems stock
INSPNYSEInspire Medical Systems, Inc., HealthcareISIN US4577301090
52Score 52 out of 100, Neutral
Price and trend
56 / 100
Price history
−33% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 5.2% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 26).
The price is 58% below its 52-week high. Largest decline in 9 years: 88% (July 2023 to May 2026).
Chart figures for advanced users
- SMA 50$68.97
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$57.53
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)26
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$40.05
- The lowest closing price of the last twelve months.
- Resistance$143.99
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Inspire Medical Systems, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $1.75B, is number 43 of 90 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $911.98M (up 13.6% year on year) and earnings of $145.42M (up 171.8%).
- For fiscal 2026, analysts expect on average revenue of $855.09M (down 6.2%) and adjusted earnings per share of $1.25 (down 51.7%).
Show more
- MEQIRI Score 52 out of 100 (Neutral): rank 369 of 714 in Healthcare, median 53.
- Our model puts fair value at $55.44, with the price 12% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 51.2% a year since 2020, Medical (Devices) median 13.8%.Growth 70
- More cash than debtCash $327.97M, financial debt $28.61M.Stability 77
- Analysts expect strong earnings growthUp 15% a year through 2028 (estimates from 10 analysts).Growth 70
Weaknesses
- Volatile share priceVolatility 70% a year over the last 12 months.
- DilutionShare count up 13% since 2020.Capital allocation 24
- Share price fell sharplyDown 33% over the last 12 months.Momentum 45
Its standout strengths are stability and growth, while fundamentals and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- high price swings
- weak fundamentals
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $36.96 and expensive above $110.87 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $46.77, at 7.8% it would be $68.39.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 0.2% on the twelve months before. Revenue has grown strongly since 2015, at around 61% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 85%, operating 6%, net 16%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 10 Feb 2027in 90 days
- Last reported
- 2 Nov 2026EPS reported $0.14 (expected $0.09)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.25+0.7%
- Revenue
- $855.09M+0.1%
- Earnings per share
- $1.47−0.4%
- Revenue
- $878.16M−1.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +27.7%2026 outlook raised for revenue, adjusted operating margin (4% to 6%) and adjusted EPS ($1.05 to $1.45).
“We now expect adjusted operating margin in the range of 4% to 6%, diluted EPS in the range of a loss of $0.42 per share to earnings of $0.17 per share and adjusted diluted EPS in the range of $1.05 to $1.45.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 3 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $201,756 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Inspire Medical Systems
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 52
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Drägerwerk AG & Co. KGaADRW3.DE $2.29B65
- Establishment Labs HoldingsESTA $2.11B41
- Butterfly NetworkBFLY $1.91B46
- ChemoMetecCHEMM.CO $1.82B77
- Embla Medical hf.EMBLA.CO $1.78B67
- EnovisENOV $1.65B45
- Medartis HoldingMED.SW $1.64B54
- VitrolifeVITR.ST $1.58B51
ETFs that hold Inspire Medical Systems
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.14% | 0.30% | €185.82M |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.11% | 0.30% | €2.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.06% | 0.30% | €2.17B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.06% | 0.30% | €4.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.48B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.02% | 0.30% | €944.34M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.02% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 13 Feb 2026)
- Valuation signal Fairly valued since 11 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.